Spearheading the Charge Against Rare Disease
The US rare and ultra-rare disease market constitutes a cornerstone of the worldwide pharmaceutical industry, representing a full 52.3 percent of the total global market share in revenue for that…
Chiesi is an international company based in Parma, Italy, with more than 80 years of experience and a strong focus on the research, development, production and commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.
Contact
Gonzagagasse 16/161010 Vienna, Austria
Tel +43 / (0)1 / 407 39 19 – 0
Website http://www.chiesi-cee.com/
Email office.at@chiesi.com
The US rare and ultra-rare disease market constitutes a cornerstone of the worldwide pharmaceutical industry, representing a full 52.3 percent of the total global market share in revenue for that…
John Hess, Senior Vice President, Americas at Chiesi Global Rare Diseases, reflects on his career journey and the evolution of Chiesi’s dedicated rare disease organisation. In this interview, he discusses…
Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across…
Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC…
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR,…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all healthcare workers, the manufacturing of Sputnik V, and recent updates from the country’s top…
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with Menarini CEO Elcin Barker Ergun, a public health management crisis in the…
Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in…
See our Cookie Privacy Policy Here
